RxDoctor Payments DataLook up a doctor →

Jennifer Levesque, PA

Medical · Fall River, MANPI 1487698908

Payments from drug & device makers

$14,656in general payments, 2019–2025

Across 721 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • LEO Pharma Inc.$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$939
  • Regeneron Healthcare Solutions, Inc.$685
  • plus $4K from 20 others

What the payments were for

  • Food & beverage$13,87295%
  • Education$7845%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,656 in reported general payments places this provider in the 95th percentile of 421 medical providers in Massachusetts.

See all medical providers in Massachusetts

Medicare billing

Part B allowed, 2024
$131,373
Medicare patients
597
Services billed
2,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$258,763
SkyriziRisankizumab-Rzaa12$240,731
TremfyaGuselkumab14$192,457
Dupixent PenDupilumab18$67,257
ZoryveRoflumilast18$15,460
Ivermectin25$4,563
Fluorouracil70$3,968
Fluocinolone Acetonide30$2,193
Mometasone Furoate132$1,901
Clobetasol Propionate21$1,755
Metronidazole36$1,667
Triamcinolone Acetonide90$1,615
Tretinoin24$1,500
Tacrolimus12$1,198
Ketoconazole62$1,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$4,279$240,73112 claims
Johnson & JohnsonTremfya$2,443$192,45714 claims
Arcutis Biotherapeutics, Inc.Zoryve$497$15,46018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 421 medical providers in Massachusetts.

Other medical in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →